


Venture Capital

2013: Emerging companies and leading venture capitalists throughout the United States and Europe turn to WilmerHale for legal advice and business advantage. Hundreds of startup companies have relied on us from formation to funding to market leadership and successful IPOs or acquisitions. In 2012, we served as counsel in more than 200 venture financings raising approximately \$1.5 billion, including some of the largest and most prominent deals of the year. Since 2005, we have handled approximately 2,000 venture financings raising over \$18 billion. We have one of the top venture capital practices in the world, and over the past decade have represented more venture capital-backed companies in the eastern half of the United States than any other law firm. The following is a selection of our recent venture capital transactions.

Counsel of Choice for Venture Capital Financings

SERVING INDUSTRY LEADERS IN TECHNOLOGY, LIFE SCIENCES, CLEANTECH, FINANCIAL SERVICES, COMMUNICATIONS AND BEYOND



 Lattice \$20,000,000 <i>Third Round</i> November 2012	 arteaus therapeutics \$18,000,000 <i>First Round</i> July 2012	 SynapDx \$6,000,000 <i>Series A-1 Round</i> November 2012	 KIOR \$55,000,000 <i>Third Round</i> April 2011	 ANNOVATION \$11,000,000 <i>First Round</i> July 2012	 {Fiksu} \$10,000,000 <i>Second Round</i> June 2012	 BOUNDLESS \$8,000,000 <i>First Round</i> January 2012	 480 biomedical \$15,000,000 <i>Second Round</i> September 2011	
 Metamark GENETICS, INC. \$13,000,000 <i>Second Round</i> November 2012	 TransMedics \$36,000,000 <i>Late Stage</i> November 2012	 Allena PHARMACEUTICALS \$15,000,000 <i>First Round</i> September 2011	 NOTUPOLIMOTION \$11,000,000 <i>Second Round</i> February 2012	 ELEVEN BIOTHERAPEUTICS \$20,500,000 (\$45,000,000 total) <i>First Round</i> April 2012	 trevi THERAPEUTICS \$10,000,000 <i>First Round</i> December 2012	 mineraltree \$6,300,000 <i>Second Round</i> June 2012	 CERULEAN \$28,000,000 <i>Fourth Round</i> December 2012	 VERACODE \$30,000,000 <i>Late Stage</i> April 2012
 NANTERO \$10,000,000 <i>Fourth Round</i> November 2012	 catabasis \$47,600,000 <i>First Round</i> December 2011	 NEXAGE \$10,000,000 <i>Second Round</i> May 2012	 7digital \$10,000,000 <i>Fourth Round</i> October 2012	 rethink robotics \$30,000,000 <i>Third Round</i> June 2012	 agios \$78,000,000 <i>Third Round</i> November 2011	 PTC THERAPEUTICS \$30,000,000 <i>Late Stage</i> May 2012	 Visterra \$26,000,000 <i>First Round</i> November 2012	
 mc10 <i>reshaping electronics</i> \$10,000,000 <i>Strategic Round</i> November 2012	 Daktari \$10,000,000 <i>Second Round</i> December 2011	 Coferon \$12,000,000 <i>Second Round</i> June 2012	 MERRIMACK PHARMACEUTICALS \$77,000,000 <i>Late Stage</i> April 2011	 tōkai pharmaceuticals \$23,000,000 <i>Fourth Round</i> September 2011	 Constellation Pharmaceuticals \$15,000,000 <i>Second Round</i> June 2011	 OvaScience <i>Improving Fertility Through Science</i> \$37,000,000 <i>Second Round</i> April 2012		



Mixed Sources
Product group from well-managed
forests, controlled sources and
recycled wood or fiber
www.fsc.org Cert no. BV-COC-070904
© 1996 Forest Stewardship Council

13_0074 RPI 2/13 3,500

WilmerHale recognizes its corporate responsibility to environmental stewardship.

wilmerhale.com

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 1875 Pennsylvania Avenue, NW, Washington, DC 20006, +1 202 663 6000. Our United Kingdom offices are operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers authorized and regulated by the Solicitors Regulation Authority (SRA No. 287488). Our professional rules can be found at www.sra.org.uk/solicitors/code-of-conduct.page. A list of partners and their professional qualifications is available for inspection at our UK offices. In Beijing, we are registered to operate as a Foreign Law Firm Representative Office. This material is for general informational purposes only and does not represent our advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all legal developments. Prior results do not guarantee a similar outcome. © 2013 Wilmer Cutler Pickering Hale and Dorr LLP